The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of IMC A12 and temsirolimus in children with refractory solid tumors: A Children’s Oncology Group study.
Maryam Fouladi
Research Funding - Merck
John Peter Perentesis
No relevant relationships to disclose
Lars M. Wagner
No relevant relationships to disclose
Ashish M Ingle
No relevant relationships to disclose
George Thomas
No relevant relationships to disclose
Darcy A. Krueger
No relevant relationships to disclose
Peter Houghton
No relevant relationships to disclose
A.A. Vinks
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose